Effect of Vitamin D Replacement on Cognition in Multiple Sclerosis Patients

Multiple Sclerosis is associated with deficient serum 25 hydroxyvitamin D (25 (OH) D) level and cognitive impairment. The aim of this study is to evaluate cognitive performance in MS patients with deficient 25 (OH) D (< 25 ng/ml) compared to patients with sufficient levels (> 35 ng/ml), then to evaluate the change in cognitive performance after 3 months of vitamin D3 oral replacement. Eighty-eight MS patients with relapsing remitting and clinically isolated type of MS, older than 18 years treated with interferon beta were enrolled. Cognitive testing was performed at baseline and at 3 months using the Montreal Cognitive Assessment (MoCA), Stroop, Symbol Digit Modalities (SDMT) and Brief Visuospatial Memory Test (BVMT-R). Serum 25 (OH) D was measured at baseline and at the end of the study. Vitamin D3 replacement improved the MS patients' cognitive performance after 3 months on the MoCA and BVMT-Delayed Recall (DR). Sufficient serum 25 (OH) D level predicted better cognitive performance on the BVMT-DR at baseline (beta: 1.74, p: < 0.008) and 3 months (beta: 1.93, p: < 0.01) after adjusting for all measured confounding variables. Vitamin D-3 replacement could improve cognitive performance in MS patients and make a significant difference in the patient's quality of life.